Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Danielle Fabian

Nurse Practitioner, Family Augusta, ME Nurse Practitioner

NPI 1134870710 CMS profile 11311535

35 Medical Center Pkwy, Augusta, ME 04330

Open in the dashboard

General payments

$1,243

52 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Fabian of Augusta, ME is reported in the CMS Open Payments database as having received $1,243 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 10
2024 General $246 10
2023 General $345 13
2022 General $405 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Fabian
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Danielle Fabian were reported at $247. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Danielle Fabian Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $405 $141 $44–$430 $149
2023 $345 $154 $49–$476 $160
2024 $246 $165 $51–$504 $164
2025 $247 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $932 40 payments
  2. Regeneron Healthcare Solutions, Inc. $137 4 payments
  3. Sanofi-Aventis U.S. LLC $46 1 payment
  4. Novartis Pharmaceuticals Corporation $40 2 payments
  5. Genzyme Corporation $32 2 payments
  6. Lilly USA, LLC $29 1 payment
  7. Greer Laboratories, Inc. $14 1 payment
  8. Aimmune Therapeutics, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,135 50 payments
  2. Education $108 2 payments
Products named General payments · program years 2022–2025
  1. FASENRA $898 39 payments
  2. DUPIXENT Immunology $111 5 payments
  3. DUPIXENT Inflammation And Immunology $86 2 payments
  4. AIRSUPRA $34 1 payment
  5. EBGLYSS $29 1 payment
  6. Rhapsido $21 1 payment
  7. XOLAIR $19 1 payment
  8. ORALAIR $14 1 payment
  9. DUPIXENT Immunology And Inflammation $14 1 payment
  10. PALFORZIA $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

204

Median for Nurse Practitioner: 389

Drug cost

$13,986

Median for Nurse Practitioner: $21,885

Branded share of claims

28.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Symbicort Budesonide/Formoterol Fumarate Brand 21 $7,226
Breyna Budesonide/Formoterol Fumarate Brand 21 $3,003
Mometasone Furoate Generic 12 $1,297
Fluticasone Propionate Generic 32 $770
Azelastine Hcl Generic 36 $718
Ipratropium Bromide Generic 15 $351
Famotidine Generic 16 $259
Albuterol Sulfate Hfa Albuterol Sulfate Brand 16 $215
Montelukast Sodium Generic 11 $101
Prednisone Generic 24 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$3,701

Medicare's payments for the services billed

Medicare patients

36

Average age 68

Services billed

418

25 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 39%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $183
$183 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record